Heidelberg Capsule I

Steinberg, Wallace H.; Mina, Faten; Pick, P; Frey, Gunther H.

doi:10.1002/jps.2600540522

Cited by 22 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that methods of telemetrically reading physical or biochemical parameters, e.g. pH measurements by means of the Heidelberg capsule (Steinberg et al 1965), could be combined with magnetic marker monitoring and thus provide the measured sensor data in real time at known positions. The most important step of further development, however, is directed at the combination of magnetic marker monitoring with drug targeting in the gastrointestinal tract.…”

Section: Discussionmentioning

confidence: 99%

A novel method for real-time magnetic marker monitoring in the gastrointestinal tract

Andrä¹,

Danan²,

Kirmße³

et al. 2000

Phys. Med. Biol.

View full text Add to dashboard Cite

In internal medicine, a simple method for the functional examination of the gastrointestinal tract without the risk of radiation exposure is required. We describe a novel principle based on the monitoring of magnetic markers which meets these demands. Our method employs a special permanent magnet which is repeatedly aligned by a vertically oriented pulsed magnetic field. Due to this alignment, the marker position can be derived from the stray field components measured by commercial field sensors. Our method was evaluated by means of a 3D intestinal phantom. The monitoring procedure yielded the time course of the marker position as a 3D plot either in real-time or as a time-lapse movie. The spatial resolution, expressed by the mean square deviation, was better than 10 mm and is thus sufficiently high to distinguish between adjacent loops of the gut. The temporal resolution, i.e. the minimum time between two successive measurements, was about 1 s. The presented method has very moderate technical demands and allows us to monitor magnetic markers in real-time. The technique may be useful with respect to functional examination of the gastrointestinal tract. In pharmaceutical research, our method offers the opportunity for remote drug release at any position of the gut.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel method for real-time magnetic marker monitoring in the gastrointestinal tract

Andrä¹,

Danan²,

Kirmße³

et al. 2000

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…To circumvent some of these disadvantages, ingestible devices were developed. Besides the exception of the "Heidelberg capsule" in 1957 for pH measurements [32], smart wireless capsules have been entering the market since 2001, with the PillCam (Given Imaging) imaging video capsule for imaging the gastrointestinal tract [33]. Since then, various other ingestible medical devices have been developed for different purposes, including smart pills for drug delivery and monitoring [34,35].…”

Section: Rationalementioning

confidence: 99%

Pilot Study: Safety and Performance Validation of an Ingestible Medical Device for Collecting Small Intestinal Liquid in Healthy Volunteers

Tronel,

Silvent,

Buelow

et al. 2024

MPs

View full text Add to dashboard Cite

The connection between imbalances in the human gut microbiota, known as dysbiosis, and various diseases has been well established. Current techniques for sampling the small intestine are both invasive for patients and costly for healthcare facilities. Most studies on human gut microbiome are conducted using faecal samples, which do not accurately represent the microbiome in the upper intestinal tract. A pilot clinical investigation, registered as NCT05477069 and sponsored by the Grenoble Alpes University Hospital, is currently underway to evaluate a novel ingestible medical device (MD) designed for collecting small intestinal liquids by Pelican Health. This study is interventional and monocentric, involving 15 healthy volunteers. The primary objective of the study is to establish the safety and the performance of the MD when used on healthy volunteers. Secondary objectives include assessing the device’s performance and demonstrating the difference between the retrieved sample from the MD and the corresponding faecal sample. Multi-omics analysis will be performed, including metagenomics, metabolomics, and culturomics. We anticipate that the MD will prove to be safe without any reported adverse effects, and we collected samples suitable for the proposed omics analyses in order to demonstrate the functionality of the MD and the clinical potential of the intestinal content.

show abstract